1. Home
  2. LBPH vs MOMO Comparison

LBPH vs MOMO Comparison

Compare LBPH & MOMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LBPH
  • MOMO
  • Stock Information
  • Founded
  • LBPH 2020
  • MOMO 2011
  • Country
  • LBPH United States
  • MOMO China
  • Employees
  • LBPH N/A
  • MOMO N/A
  • Industry
  • LBPH Biotechnology: Pharmaceutical Preparations
  • MOMO Computer Software: Prepackaged Software
  • Sector
  • LBPH Health Care
  • MOMO Technology
  • Exchange
  • LBPH Nasdaq
  • MOMO Nasdaq
  • Market Cap
  • LBPH 1.4B
  • MOMO 1.2B
  • IPO Year
  • LBPH 2021
  • MOMO 2014
  • Fundamental
  • Price
  • LBPH $59.81
  • MOMO $6.40
  • Analyst Decision
  • LBPH Buy
  • MOMO Buy
  • Analyst Count
  • LBPH 8
  • MOMO 3
  • Target Price
  • LBPH $52.29
  • MOMO $8.23
  • AVG Volume (30 Days)
  • LBPH 834.8K
  • MOMO 774.5K
  • Earning Date
  • LBPH 11-07-2024
  • MOMO 12-09-2024
  • Dividend Yield
  • LBPH N/A
  • MOMO 8.29%
  • EPS Growth
  • LBPH N/A
  • MOMO N/A
  • EPS
  • LBPH N/A
  • MOMO 0.99
  • Revenue
  • LBPH N/A
  • MOMO $1,554,664,297.00
  • Revenue This Year
  • LBPH N/A
  • MOMO N/A
  • Revenue Next Year
  • LBPH N/A
  • MOMO N/A
  • P/E Ratio
  • LBPH N/A
  • MOMO $6.74
  • Revenue Growth
  • LBPH N/A
  • MOMO N/A
  • 52 Week Low
  • LBPH $3.60
  • MOMO $4.79
  • 52 Week High
  • LBPH $59.95
  • MOMO $8.19
  • Technical
  • Relative Strength Index (RSI)
  • LBPH 78.81
  • MOMO 36.35
  • Support Level
  • LBPH $59.47
  • MOMO $6.60
  • Resistance Level
  • LBPH $59.85
  • MOMO $6.94
  • Average True Range (ATR)
  • LBPH 0.20
  • MOMO 0.23
  • MACD
  • LBPH -0.84
  • MOMO -0.05
  • Stochastic Oscillator
  • LBPH 86.36
  • MOMO 0.45

About LBPH Longboard Pharmaceuticals Inc.

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.

About MOMO Hello Group Inc.

Hello Group Inc provides mobile-based social networking services. It enables users to establish and expand social relationships based on location and interests. Its platform includes the Momo mobile application and a variety of related features, functionalities, tools, and services that it provides to users, customers, and platform partners. The company derives its revenue from live video services, value-added services, mobile marketing services, mobile games, and other services. It operates in three segments: Momo's service lines, Tantan's service lines, and QOOL's service lines out of which Momo's service lines segment derives the majority of revenue.

Share on Social Networks: